tesofensine legal FAQ

Provide the requested documentation immediately: supplier invoice showing research use designation, institutional purchase order, approved research protocol summary, and MSDS. Most holds resolve within 7–14 days once CBP verifies research intent. If the hold extends beyond 21 days, contact the supplier to confirm proper customs declarations were filed. Incomplete or incorrect paperwork is the usual culprit. Do not attempt to retrieve the package without institutional legal counsel review if CBP requests additional justification.

Refuse the order. A missing CoA means you cannot verify compound purity, and more critically, you lack documentation proving the substance you received matches what you ordered. Regulatory inspections, institutional audits, and customs reviews all require CoA verification. A supplier operating without third-party purity testing is either unlicensed or cutting corners that create legal exposure for buyers. Request the CoA before payment. Legitimate suppliers provide it without hesitation.

You cannot establish compliant procurement intent under most supplier terms of service. The legal path requires institutional oversight. Either through university affiliation, a private research facility with IRB/IACUC protocols, or a registered contract research organization (CRO). Some researchers address this by partnering with an academic institution as a visiting researcher or adjunct faculty member, gaining access to institutional procurement systems. Without that affiliation, suppliers classify your order as non-research intent, which most refuse to fulfill.

Request certificates of analysis (CoA) for every batch, verify the supplier operates under FDA-registered facilities where applicable, and confirm the supplier does not market products with human-use language. Reputable suppliers like Real Peptides provide HPLC purity verification, molecular weight confirmation, and storage guidelines with every shipment. Your institutional review board (IRB) or ethics committee will require this documentation for protocol approval. If a supplier cannot provide batch-specific CoAs or uses promotional language suggesting therapeutic use, find a different vendor.

Yes. Purchasing tesofensine for personal consumption violates federal misbranding statutes because the compound is explicitly marketed for research use only. Even if the supplier ships the product, your stated or implied intent to use it therapeutically constitutes illegal off-label use of an unapproved drug. Federal prosecutors have pursued cases where individuals purchased research chemicals for personal use and experienced adverse events—particularly when those events required medical intervention. The legal risk compounds if you resell or distribute the compound to others.

Refuse. No licensed physician can legally prescribe tesofensine in 2026 because it is not an FDA-approved pharmaceutical product. Any doctor offering to prescribe it is either operating outside their scope of practice or misrepresenting a research-grade compound as a prescription medication. This exposes both the physician to medical board sanctions and the patient to unregulated dosing of a cardiovascular-active compound without proper safety monitoring. The tesofensine legal 2026 status provides no prescription pathway—period.